Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1α using PX-478

Bénédicte F. Jordan, Matthew Runquist, Natarajan Raghunand, Amanda F Baker, Ryan Williams, Lynn Kirkpatrick, Garth Powis, Robert J. Gillies

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

PX-478 is a new agent known to inhibit the hypoxia-responsive transcription factor, HIF-1α, in experimental tumors. The current study was undertaken in preparation for clinical trials to determine which noninvasive imaging endpoint(s) is sensitive to this drug's actions. Dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) were used to monitor acute effects on tumor hemodynamics and cellularity, respectively. Mice bearing human xenografts were treated either with PX-478 or vehicle, and imaged over time. DW imaging was performed at three b values to generate apparent diffusion coefficient of water (ADCw) maps. For DCE-MRI, a macromolecular contrast reagent, BSA-Gd-DTPA, was used to determine vascular permeability and vascular volume fractions. PX-478 induced a dramatic reduction in tumor blood vessel permeability within 2 hours after treatment, which returned to baseline by 48 hours. The anti-VEGF antibody, Avastin, reduced both the permeability and vascular volume. PX-478 had no effect on the perfusion behavior of a drug-resistant tumor system, A-549. Tumor cellularity, estimated from ADCw, was significantly decreased 24 and 36 hours after treatment. This is the earliest significant response of ADC to therapy yet reported. Based on these pre-clinical findings, both of these imaging endpoints will be included in the clinical trial of PX-478.

Original languageEnglish (US)
Pages (from-to)475-485
Number of pages11
JournalNeoplasia
Volume7
Issue number5
DOIs
StatePublished - May 2005

Fingerprint

Diffusion Magnetic Resonance Imaging
Tumor Microenvironment
Capillary Permeability
Neoplasms
Clinical Trials
Vascular Tissue Neoplasms
Gadolinium DTPA
Water
Heterografts
Pharmaceutical Preparations
Vascular Endothelial Growth Factor A
Blood Vessels
Anti-Idiotypic Antibodies
Permeability
Transcription Factors
Perfusion
Hemodynamics
Magnetic Resonance Imaging
2-amino-3-(4'-N,N-bis(2-chloroethyl)amino)phenylpropionic acid N-oxide

Keywords

  • Diffusion Magnetic Resonance Imaging
  • Dynamic Contrast-Enhanced Magnetic Resonance Imaging
  • HT-29 tumors
  • Molecular imaging
  • PX-478

ASJC Scopus subject areas

  • Cancer Research

Cite this

Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1α using PX-478. / Jordan, Bénédicte F.; Runquist, Matthew; Raghunand, Natarajan; Baker, Amanda F; Williams, Ryan; Kirkpatrick, Lynn; Powis, Garth; Gillies, Robert J.

In: Neoplasia, Vol. 7, No. 5, 05.2005, p. 475-485.

Research output: Contribution to journalArticle

Jordan, Bénédicte F. ; Runquist, Matthew ; Raghunand, Natarajan ; Baker, Amanda F ; Williams, Ryan ; Kirkpatrick, Lynn ; Powis, Garth ; Gillies, Robert J. / Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1α using PX-478. In: Neoplasia. 2005 ; Vol. 7, No. 5. pp. 475-485.
@article{5062c1f832794b89a9bd0c1e673509d4,
title = "Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1α using PX-478",
abstract = "PX-478 is a new agent known to inhibit the hypoxia-responsive transcription factor, HIF-1α, in experimental tumors. The current study was undertaken in preparation for clinical trials to determine which noninvasive imaging endpoint(s) is sensitive to this drug's actions. Dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) were used to monitor acute effects on tumor hemodynamics and cellularity, respectively. Mice bearing human xenografts were treated either with PX-478 or vehicle, and imaged over time. DW imaging was performed at three b values to generate apparent diffusion coefficient of water (ADCw) maps. For DCE-MRI, a macromolecular contrast reagent, BSA-Gd-DTPA, was used to determine vascular permeability and vascular volume fractions. PX-478 induced a dramatic reduction in tumor blood vessel permeability within 2 hours after treatment, which returned to baseline by 48 hours. The anti-VEGF antibody, Avastin, reduced both the permeability and vascular volume. PX-478 had no effect on the perfusion behavior of a drug-resistant tumor system, A-549. Tumor cellularity, estimated from ADCw, was significantly decreased 24 and 36 hours after treatment. This is the earliest significant response of ADC to therapy yet reported. Based on these pre-clinical findings, both of these imaging endpoints will be included in the clinical trial of PX-478.",
keywords = "Diffusion Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, HT-29 tumors, Molecular imaging, PX-478",
author = "Jordan, {B{\'e}n{\'e}dicte F.} and Matthew Runquist and Natarajan Raghunand and Baker, {Amanda F} and Ryan Williams and Lynn Kirkpatrick and Garth Powis and Gillies, {Robert J.}",
year = "2005",
month = "5",
doi = "10.1593/neo.04628",
language = "English (US)",
volume = "7",
pages = "475--485",
journal = "Neoplasia",
issn = "1522-8002",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1α using PX-478

AU - Jordan, Bénédicte F.

AU - Runquist, Matthew

AU - Raghunand, Natarajan

AU - Baker, Amanda F

AU - Williams, Ryan

AU - Kirkpatrick, Lynn

AU - Powis, Garth

AU - Gillies, Robert J.

PY - 2005/5

Y1 - 2005/5

N2 - PX-478 is a new agent known to inhibit the hypoxia-responsive transcription factor, HIF-1α, in experimental tumors. The current study was undertaken in preparation for clinical trials to determine which noninvasive imaging endpoint(s) is sensitive to this drug's actions. Dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) were used to monitor acute effects on tumor hemodynamics and cellularity, respectively. Mice bearing human xenografts were treated either with PX-478 or vehicle, and imaged over time. DW imaging was performed at three b values to generate apparent diffusion coefficient of water (ADCw) maps. For DCE-MRI, a macromolecular contrast reagent, BSA-Gd-DTPA, was used to determine vascular permeability and vascular volume fractions. PX-478 induced a dramatic reduction in tumor blood vessel permeability within 2 hours after treatment, which returned to baseline by 48 hours. The anti-VEGF antibody, Avastin, reduced both the permeability and vascular volume. PX-478 had no effect on the perfusion behavior of a drug-resistant tumor system, A-549. Tumor cellularity, estimated from ADCw, was significantly decreased 24 and 36 hours after treatment. This is the earliest significant response of ADC to therapy yet reported. Based on these pre-clinical findings, both of these imaging endpoints will be included in the clinical trial of PX-478.

AB - PX-478 is a new agent known to inhibit the hypoxia-responsive transcription factor, HIF-1α, in experimental tumors. The current study was undertaken in preparation for clinical trials to determine which noninvasive imaging endpoint(s) is sensitive to this drug's actions. Dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) magnetic resonance imaging (MRI) were used to monitor acute effects on tumor hemodynamics and cellularity, respectively. Mice bearing human xenografts were treated either with PX-478 or vehicle, and imaged over time. DW imaging was performed at three b values to generate apparent diffusion coefficient of water (ADCw) maps. For DCE-MRI, a macromolecular contrast reagent, BSA-Gd-DTPA, was used to determine vascular permeability and vascular volume fractions. PX-478 induced a dramatic reduction in tumor blood vessel permeability within 2 hours after treatment, which returned to baseline by 48 hours. The anti-VEGF antibody, Avastin, reduced both the permeability and vascular volume. PX-478 had no effect on the perfusion behavior of a drug-resistant tumor system, A-549. Tumor cellularity, estimated from ADCw, was significantly decreased 24 and 36 hours after treatment. This is the earliest significant response of ADC to therapy yet reported. Based on these pre-clinical findings, both of these imaging endpoints will be included in the clinical trial of PX-478.

KW - Diffusion Magnetic Resonance Imaging

KW - Dynamic Contrast-Enhanced Magnetic Resonance Imaging

KW - HT-29 tumors

KW - Molecular imaging

KW - PX-478

UR - http://www.scopus.com/inward/record.url?scp=20444430874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444430874&partnerID=8YFLogxK

U2 - 10.1593/neo.04628

DO - 10.1593/neo.04628

M3 - Article

C2 - 15967100

AN - SCOPUS:20444430874

VL - 7

SP - 475

EP - 485

JO - Neoplasia

JF - Neoplasia

SN - 1522-8002

IS - 5

ER -